The SERM, Arzoxifene, and the Rexinoid, LG100268, Cooperate to Prevent Estrogen Receptor-Positive and -Negative Breast Cancer as Well as Colon Cancer.

doi 10.1349/ddlp.37
Full Text
Abstract

Available in full text

Date

Unknown

Authors
Publisher

Dartmouth College Library Press

Related search

Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

How to Target Estrogen Receptor-Negative Breast Cancer?

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2003English

Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268

Clinical Cancer Research
Cancer ResearchOncology
2008English

The Estrogen Receptor and Its Variants as Risk Factors in Breast Cancer

2001English

Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2011English

Androgen Receptor-Positive, Triple-Negative Breast Cancer

Cancer
Cancer ResearchOncology
2017English

Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer

2013English

Characterization of the Interactions Between Calmodulin and Death Receptor 5 in Triple-Negative and Estrogen Receptor-Positive Breast Cancer Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2016English

Targeting Proteasome-Associated Deubiquitinases as a Novel Strategy for the Treatment of Estrogen Receptor-Positive Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy